RxDoctor Payments Data

Mariliz Britton

Family · Loxahatchee, FLNPI 1053840090

Payments from drug & device makers

$8,277in general payments, 2019–2025

Across 430 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Novo Nordisk$570
  • Bristol Myers Squibb$258
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$8,11398%
  • Education$1642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,277 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$3,541
Medicare patients
32
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide62$44,799
Mesalamine ErMesalamine22$2,498
Famotidine168$1,742
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates24$1,526
Pantoprazole Sodium134$1,021
CholestyramineCholestyramine (With Sugar)13$921
Omeprazole97$859
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl52$826
Sucralfate14$353
Lactulose13$161
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl11$154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,545$44,79962 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Loxahatchee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →